BIIB vs MRNA
Biogen Inc. and Moderna, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | BIIB | MRNA |
|---|---|---|
| Revenue | $9.9B | $1.9B |
| Net income | $1.3B | $-2.8B |
| Gross margin | 75.7% | 55.3% |
| Net margin | 13.1% | −145.2% |
| Return on equity | 7.4% | −28.9% |
| Diluted EPS | $8.79 | −$7.26 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $2.1B | $-2.1B |
| Equity | · | $8.7B |
| Net debt / equity | 0.18× | −0.23× |
| Current ratio | 2.68× | 3.29× |
| Revenue CAGR 5y | −6.0% | 19.3% |
| Profit CAGR 5y | −20.2% | · |
BIIB bills 5.1× the revenue of MRNA, and MRNA closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | BIIB | MRNA |
|---|---|---|
| FY2025 | $9.9B | $1.9B |
| FY2024 | $9.7B | $3.2B |
| FY2023 | $9.8B | $6.8B |
| FY2022 | $10.2B | $19.3B |
| FY2021 | $11.0B | $18.5B |
| FY2020 | $13.4B | $803.0M |
| FY2019 | $14.4B | $60.0M |
| FY2018 | $13.5B | $135.1M |
| FY2017 | $12.3B | $205.8M |
| FY2016 | $11.4B | $108.4M |
Bottom line
| Fiscal year | BIIB | MRNA |
|---|---|---|
| FY2025 | $1.3B | $-2.8B |
| FY2024 | $1.6B | $-3.6B |
| FY2023 | $1.2B | $-4.7B |
| FY2022 | $3.0B | $8.4B |
| FY2021 | $1.6B | $12.2B |
| FY2020 | $4.0B | $-747.0M |
| FY2019 | $5.9B | $-514.0M |
| FY2018 | $4.4B | $-384.7M |
| FY2017 | $2.5B | $-255.9M |
| FY2016 | $3.7B | $-216.2M |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$7,946,600,000 | BIIB |
| FY2024 | +$6,439,900,000 | BIIB |
| FY2023 | +$2,987,600,000 | BIIB |
| FY2022 | −$9,089,600,000 | MRNA |
| FY2021 | −$7,489,300,000 | MRNA |
| FY2020 | +$12,641,600,000 | BIIB |
| FY2019 | +$14,317,900,000 | BIIB |
| FY2018 | +$13,317,832,000 | BIIB |
| FY2017 | +$12,068,075,000 | BIIB |
| FY2016 | +$11,340,404,000 | BIIB |
The higher-revenue side has changed between BIIB and MRNA over this period. The gap has narrowed since the earliest year compared.
10 of 19 comparable fiscal years — a year missing data on either side is not counted.
9 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +158.2 pp | BIIB |
| FY2024 | +126.9 pp | BIIB |
| FY2023 | +80.6 pp | BIIB |
| FY2022 | −14.3 pp | MRNA |
| FY2020 | +123.2 pp | BIIB |
| FY2019 | +897.6 pp | BIIB |
| FY2018 | +318.1 pp | BIIB |
| FY2017 | +146.1 pp | BIIB |
| FY2016 | +231.7 pp | BIIB |
The higher net margin has changed hands between BIIB and MRNA over this period.
9 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MRNA's net margin has been more volatile than BIIB's over the 9 comparable fiscal years — 245.6 percentage points of standard deviation against 9.5.
9 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between BIIB and MRNA over these 9 fiscal years — BIIB led in 8 and MRNA in 1.
9 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MRNA's return on equity has been more volatile than BIIB's over the 7 comparable fiscal years — 64.6 percentage points of standard deviation against 13.3.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between BIIB and MRNA over these 7 fiscal years — BIIB led in 5 and MRNA in 2.
7 of 19 comparable fiscal years — a year missing data on either side is not counted.